An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer

Yu Katayose, Hideo Ohtsuka, Yo Kitamura, Kunihiro Masuda, Kei Nakagawa, Kuniharu Yamamoto, Hiroshi Yoshida, Tohru Onogawa, Fuyuhiko Motoi, Takeshi Naitoh, Toshiki Rikiyama, Shin Ichi Egawa, Michiaki Unno

研究成果: Article査読

8 被引用数 (Scopus)

抄録

Background/Aims: Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC). However, few studies have been conducted to analyze second-line therapies. Methodology: From 33 patients who had been administered gemcitabine following resection between May 2005 and August 2007, we retrospectively analyzed the safety and efficacy of S-1 in 11 cases who received S-1 as second-line therapy due to recurrence or relapse of the primary disease. Results: Among the adverse events (AEs) observed during S-1 administration, the most common was a decrease in the concentration of hemoglobin, followed by thrombocytopenia. No Grade 4 AEs or worse were detected. In addition, the AEs and their respective severity strongly resembled those of gemcitabine used as a first-line therapy. There were 7 cases that could be evaluated according to RECIST criteria, of which 1 was considered in the partial response and 3 as stable disease. The medians of time to progression after S-1 administration and survival after S-1 administration were 5.6 months and 31 months, respectively. Conclusions: S-1 could be taken safely as a second-line therapy without provoking severe AEs. By preventing the cessation of S-1 administration due to its AEs, more continued S-1 administration could lead to a better prognosis for BTC.

本文言語English
ページ(範囲)691-695
ページ数5
ジャーナルHepato-Gastroenterology
59
115
DOI
出版ステータスPublished - 2012 5

ASJC Scopus subject areas

  • 肝臓学
  • 消化器病学

フィンガープリント

「An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル